Expert Reviews in Molecular Medicine

Review Article

Targeting the hypoxia-inducible factor (HIF) pathway in cancer

Evon Poona1, Adrian L. Harrisa2 and Margaret Ashcrofta1 c1

a1 Centre for Cell Signalling and Molecular Genetics, University College London, Division of Medicine, London, UK.

a2 Cancer Research UK Department of Medical Oncology, The Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK.

Abstract

The central component of hypoxia sensing in the cell is the hypoxia-inducible factor (HIF) transcriptional complex. HIF activity is deregulated in many human cancers, especially those that are highly hypoxic. Hypoxic tumour cells are usually resistant to radiotherapy and most conventional chemotherapeutic agents, rendering them highly aggressive and metastatic. Overexpression of HIF-α, the regulatory subunit of HIF, is associated with increased vascular density, severity of tumour grade, treatment failure and a poor prognostic outcome with conventional therapies. Therefore HIF is an attractive, although challenging, therapeutic target, and several different strategies have been developed to target HIF directly or indirectly in recent years. This review outlines the preclinical and clinical advances in this arena and discusses which cancers may benefit from HIF-targeted therapy.

Correspondence

c1 Corresponding author: Margaret Ashcroft, Centre for Cell Signalling and Molecular Genetics, University College London, Division of Medicine, Rayne Building, 5 University Street, London, WC1E 6JJ, UK. Tel: +44 (0)20 7679 6205; Fax: +44 (0)20 7679 6211; E-mail: m.ashcroft@ucl.ac.uk